Welcome to our dedicated page for Balchem SEC filings (Ticker: BCPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Balchem Corporation filings document financial results, governance matters, shareholder votes, and material events for a specialty ingredient manufacturer with Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products segments. Form 8-K reports attach quarterly and annual earnings releases with segment performance, cash flow measures, balance sheet items, debt, and capital-allocation disclosures.
Proxy and shareholder-meeting filings describe board elections, auditor ratification, advisory executive-compensation votes, meeting procedures, corporate governance practices, and executive compensation. Other material-event reports record officer transitions and related governance disclosures, while exhibit and Inline XBRL records support the company’s public reporting framework.
Balchem Corporation director Daniel E. Knutson reported an equity award of company stock. On 02/11/2026, he acquired 870 shares of Balchem common stock as a grant or award at a stated price of $0 per share, increasing his directly held stake to 6,899 shares.
The award is in the form of restricted stock that vests one year after the grant date. Until vesting, the shares are subject to transfer restrictions under a Restricted Stock Grant Agreement between Balchem and Knutson, meaning he must satisfy those conditions before the shares fully vest.
Wineinger Matthew David reported acquisition or exercise transactions in a Form 4 filing for BCPC. The filing lists transactions totaling 870 shares. Following the reported transactions, holdings were 8,012 shares.
Kathleen B. Fish, a director of the issuer with ticker BCPC, received a grant of 870 shares of common stock on February 11, 2026. The filing classifies this as an acquisition of non-derivative securities at a price of $0 per share.
The 870 shares are restricted stock that will vest one year after the grant date, and are subject to transfer restrictions under a Restricted Stock Grant Agreement between the company and the director. Following this award, Fish beneficially owns 3,429 shares of common stock directly.
CORP director David B. Fischer reported an acquisition of common stock through a restricted stock award. On February 11, 2026, he received 870 shares at a price of $0, characterized as a grant or award. These restricted shares vest in one year under a Restricted Stock Grant Agreement with the company. Following this transaction, Fischer directly holds 8,859 shares of CORP common stock.
Director Monica Vicente reported an acquisition of CORP common stock through an equity award. On February 11, 2026, she received 870 shares of restricted common stock at a stated price of $0 per share, increasing her direct holdings to 2,390 shares. According to the footnote, this restricted stock will vest in her name one year after the grant date and is subject to transfer restrictions set out in a Restricted Stock Grant Agreement between CORP and Vicente.
CORP vice president and chief accounting officer William A. Backus reported a routine tax-related share withholding. On 02/08/2026, 322 shares of common stock were withheld at $173.16 per share to cover taxes due on the vesting of restricted shares originally granted on 2/8/2023.
After this withholding, Backus beneficially owned 5,517 shares of CORP common stock directly and 283 shares indirectly through a 401(k) plan. The filing reflects administrative share withholding rather than an open-market sale.
BCPC’s executive vice president, chief legal officer, and secretary reported a routine tax-related share withholding. On 02/08/2026, 343 shares of common stock were disposed of at $173.16 per share to cover withholding taxes due upon vesting of restricted shares granted on 02/08/2023.
After this transaction, the officer beneficially owned 5,846 common shares directly and 487 common shares indirectly through a 401(k) plan.
Backus William A., VP & Chief Accounting Officer of CORP (BCPC), reported a routine share withholding related to equity compensation. On 04/01/2025, 383 shares of common stock at $167.24 per share were withheld to cover taxes upon vesting of restricted shares granted on 4/1/2022.
After this transaction, he beneficially owned 5,839 common shares directly and 256 common shares indirectly through a 401(k) plan as of 4/1/2025. The report notes it was an inadvertent late filing caused by an administrative error.
An officer of the issuer with ticker BCPC, SVP and GM, Specialty Products Job Leonard van Gunsteren, reported a routine tax-related share withholding. On February 8, 2026, 258 shares of common stock were withheld at $173.16 per share to cover taxes due on the vesting of restricted shares granted on February 8, 2023.
After this withholding, van Gunsteren directly beneficially owns 9,188 shares of the company’s common stock. The transaction was coded “F,” indicating a tax withholding in connection with an equity award vesting rather than an open-market sale.
Balchem Corporation’s Chairman, President & CEO Theodore L. Harris reported a tax-related share withholding in company stock. On 02/08/2026, 3,225 shares of common stock were withheld at $173.16 per share to cover withholding taxes upon vesting of restricted shares granted on 2/8/2023.
Following this transaction, Harris directly beneficially owns 75,934 shares of common stock. In addition, 2,007 shares are held indirectly through a 401(k) Plan. A further 1,022.58 shares are held in a trust for the benefit of his mother, where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.